HSIC

Business profile & competitive position

Henry Schein, Inc. operates in the Healthcare sector, specifically the Medical - Distribution industry, as a health care solutions company serving office-based dental and medical practitioners plus alternate sites of care. Its operations are organized into three reportable segments. The Global Distribution and Value-Added Services segment moves dental and medical merchandise, equipment, repair services, pharmaceuticals, vaccines, and related services. Global Specialty Products manufactures and markets dental implants, biomaterials, endodontic, orthodontic, and orthopedic products. Global Technology develops practice management software, e-services, and technology-enabled products for providers.

The company’s physical footprint is a key part of its model: 38 distribution centers covering more than 5.4 million square feet, 17 manufacturing facilities covering roughly 0.6 million square feet, and a stocked selection of more than 300,000 products. It ships an average of approximately 150,000 cartons daily and runs 127 equipment sales and service centers worldwide. The technology platform had an active user base of about 95,000 practices and 324,000 consumers as of December 27, 2025.

Those scale numbers help explain why Henry Schein can compete as a broad-line distributor, but the profitability numbers tell the margin story. The company’s net margin is 3.0% and its return on equity is 12.4%. A sub-4% net margin is consistent with a high-volume, low-margin distribution business where competitive advantage comes from selection, logistics reach, and customer relationships rather than fat pricing power. The 12.4% ROE shows the company is converting equity into profits at a moderate rate, but it does not point to a wide structural moat in the way a software or branded-pharma enterprise might show. In short, Henry Schein’s competitive position rests on distribution density, product breadth, and embedded relationships with dental and medical offices.

Financial posture

Henry Schein’s current market capitalization is $10.2 billion and the stock trades at a price-to-earnings ratio of 25.8, with the most recent price at $89.40. That P/E sits well above the 3.0% net margin and 12.4% ROE, meaning the market is pricing in expectations beyond current reported profitability. The beta of 0.81 indicates the stock has historically been somewhat less volatile than the broader market, fitting the defensive, non-discretionary character of much of the health care distribution space.

From a technical snapshot, the RSI is 58.8, which is close to neutral, and the 50-day exponential moving average is $85.61. The current price of $89.40 means the stock is trading a few percentage points above that short-term moving average.

Putting the numbers together, Henry Schein’s valuation looks more growth- and execution-sensitive than deep-value. A 25.8 P/E on a 3.0% net margin leaves limited room for operational disappointment, because the valuation ratio implies investors expect margin improvement, capital-return efficiency, or above-trend earnings growth. The recent 2026 outlook raise supports that narrative, but the math also shows why execution on cost discipline and the newer software/specialty businesses matters so much.

Strategic priorities & outlook

In its most recent SEC 10-K filing, Henry Schein laid out a set of near-term operational priorities centered on integration and digital expansion. The company is pursuing the BOLD+1 strategic plan, which is aimed at building complementary software, specialty, and services businesses in areas the company believes offer higher growth. A second priority is operationalizing “One Distribution,” a program designed to improve customer experience, generate efficiencies, and support growth across the network. In parallel, the company is using “One Schein” to broaden and deepen customer relationships across segments.

The fourth stated priority is digital transformation, both for customers and for Henry Schein itself. Given the Global Technology segment’s footprint—roughly 95,000 active practices and 324,000 consumers—software and e-services appear to be the main levers for that transformation. These priorities suggest management is focused on moving beyond pure merchandise distribution toward stickier, recurring-revenue streams without abandoning the core logistics engine.

Macro & geopolitical exposure

As a health care distributor, Henry Schein sits in a segment that is structurally exposed to several macro themes. Regulation is a constant factor: medical devices, pharmaceuticals, and vaccines are subject to FDA oversight, state licensing rules, and anti-kickback laws, so changes in enforcement or reimbursement rules can affect what products are sold and how margins are structured. The company’s dental and medical practitioner customers depend on patient visit volume and reimbursement rates, so any pressure on private insurance or government payers can flow through to equipment and consumable demand.

Supply chain and trade policy are also relevant. Much of the world’s dental and medical equipment, components, and personal protective gear is produced internationally, so tariffs, port congestion, or currency swings can influence both cost of goods and inventory turns. Foreign exchange risk matters because Henry Schein’s global distribution network sources and sells across multiple currencies. Meanwhile, commodity-price fluctuations affect resin, metals, and packaging costs, which can pressure the already-thin 3.0% net margin if they cannot be passed on to customers. Finally, public-health trends—whether routine vaccination schedules, infection-control protocols, or dental utilization patterns—can drive meaningful short-term demand shifts for distributors.

Recent developments

The most recent news flow around Henry Schein has been broadly positive, though not without caution notes. On August 18, 2026, Zacks reported that Henry Schein “Raised 2026 Outlook as Sales and Margin Momentum Accelerates,” following the August 4, 2026 earnings release. That same day, Defense World noted that Empowered Funds LLC held an $851,000 position in the company, reflecting continued institutional attention.

On August 19, 2026, Zacks asked whether the stock was worth buying as growth improved but execution risks persisted—a framing that captures the tension between the improved 2026 guidance and the still-elevated P/E relative to underlying margins. Two days later, on August 21, 2026, Zacks again highlighted Henry Schein as a “Top Value Stock for the Long-Term.” Taken together, the headlines suggest analysts are watching whether the company can convert its BOLD+1 and One Distribution plans into sustained margin expansion that justifies the current valuation.

Earnings behavior & post-earnings drift

Henry Schein has a solid, yet selective, earnings track record over the last eight reported quarters, with a beat rate of 6 out of 8, or 75%. The average earnings surprise across those quarters is 2.9%. Despite the tendency to exceed estimates, the stock’s average five-day move after earnings across the same period is -2.05%, classified as a downward post-earnings drift.

The last four reports illustrate that dynamic clearly. On August 4, 2026, the company reported EPS of $1.27 against a $1.24 estimate, a 2.4% beat; the stock rose 0.54% the next day and finished up 0.08% over the following five sessions. On May 5, 2026, EPS came in at $1.32 versus a $1.20 estimate, a 10% surprise, yet the stock fell 2.6% the next day and dropped 6.75% over the following five days. On February 24, 2026, EPS of $1.34 beat the $1.30 estimate by 3.1%, but the stock fell 1.73% the next day and 3.77% over the next five. The November 4, 2025 report was the exception in this recent window: EPS of $1.38 versus $1.27, an 8.7% beat, drove a 0.56% next-day gain and a 2.25% five-day gain.

This pattern—beats outpacing estimates while the stock often sells off after the report—suggests the market’s real expectation heading into print may be higher than the published consensus, and that good results are sometimes cheered less than the magnitude of the surprise would imply. The next scheduled earnings release is November 3, 2026, before the market open, with the current consensus EPS estimate at $1.35.

For investors who want a more complete picture of how institutional analysts, quant models, and options positioning align around Henry Schein ahead of the November 3, 2026 report, exploring the full institutional verdict is a useful next step.